Released : April 08, 2019 07:00 RNS Number : 3613V MaxCyte, Inc. 08 April 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte® Launches ExPERT™ Instrument Family to Provide a Unifying Technology Platform from Concept to Commercialization for Next-Generation Cellular Therapies
Released : March 26, 2019 07:00 RNS Number : 9554T MaxCyte, Inc. 26 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Full Year Results Gaithersburg, Maryland - 26 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, will be
Released : March 19, 2019 17:05 RNS Number : 3554T MaxCyte, Inc. 19 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Director Dealings Issue of Equity Gaithersburg, Maryland - 19 March 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company,
Released : March 01, 2019 07:00 RNS Number : 5188R MaxCyte, Inc. 01 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company Gaithersburg, Maryland - 01 March 2019: MaxCyte (LSE: MXCT, MXCS),
Released : February 26, 2019 17:32 RNS Number : 1971R MaxCyte, Inc. 26 February 2019 THIS ANNOUNCEMENT IS RESTRICTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES (OR TO ANY US PERSON), CANADA , AUSTRALIA , JAPAN OR
Released : February 05, 2019 16:32 RNS Number : 1641P MaxCyte, Inc. 05 February 2019 THIS ANNOUNCEMENT IS RESTRUCTED AND NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH
Released : February 05, 2019 07:00 RNS Number : 0847P MaxCyte, Inc. 05 February 2019 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES , CANADA , AUSTRALIA , JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION
Released : March 05, 2019 07:00 RNS Number : 8081R MaxCyte, Inc. 05 March 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 05 March 2019 : MaxCyte (LSE: MXCT, MXCS ), the global cell-based medicines and life sciences company , announces that on 04
Released : January 15, 2019 07:00 RNS Number : 0746N MaxCyte, Inc. 15 January 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Strong CARMA ™ and financial progress: 19% revenue growth and EBITDA ahead of expectations Gaithersburg, Maryland - 15 JANUARY 2019: MaxCyte
Released : December 19, 2018 07:00 RNS Number : 8667K MaxCyte, Inc. 19 December 2018 MaxCyte, Inc. ("MaxCyte" or the "Company") Change of Auditor Gaithersburg, Maryland - 19 DECEMBER 2018: MaxCyte (LSE: MXCT), the global cell-based medicines and life sciences company, is pleased to
